Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Multiple thoughts.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5566)
•••
Comment by Noteableon Jun 14, 2024 11:12am
44 Views
Post# 36089190

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Multiple thoughts.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Multiple thoughts.Washington — The federal judge overseeing special counsel Jack Smith's classified documents case against Donald Trump once again rejected requests by the former president's legal team to dismiss the charges against him, according to an order filed Monday evening. 

The difference between Biden and Trump is that Biden voluntarily surrendered all government documents he possesed while Trump has intentionally prevented his surrender of any documents that he absconded with and currently possesses.

Under the Presidential Records Act of 1978, once a president’s term ends, all presidential and vice presidential records must be turned over to NARA. This only applies to records made after 1981, when Ronald Reagan began his first term. Paper memos, emails, texts, voice memos, scraps of paper with scribbled notes for an upcoming speech—anything that is “related to their acts as president” falls under NARA’s jurisdiction, according to Dan Cohen, dean of libraries at Northeastern University. 

But in an upcoming book by reporter Maggie Haberman, she alleges that Trump tore up documents and tried to flush them down the toilet.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities